Conmed vs Enovis
CNMD and ENOV side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CNMD and ENOV compare
Conmed and Enovis are about the same size, with market caps of $1.5B and $1.6B.
Enovis grew revenue faster over the last twelve months (4.9% versus 1.6% for Conmed).
Conmed keeps more of each dollar of sales as profit, with a net margin of 5.4% compared with −48.0% at Enovis.
Conmed scores higher on the StockData Score (14 against 8 for Enovis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CNMD | ENOV |
|---|---|---|
| Size and price | ||
| Market cap | $1.5B | $1.6B |
| Share price | $49.35 | $27.92 |
| Change, 1 year | 14.1% | −9.6% |
| Change, 5 years | −63.5% | −80.8% |
| Beta (5Y) | 0.35 | 0.04 |
| Employees | 3,900 | 7,802 |
| StockData Score | ||
| Total score | 14 (better) | 8 |
| Valuation score | 6 (better) | 4 |
| Growth score | 2 | 2 |
| Performance score | 4 (better) | 0 |
| Health score | 2 | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 20.4× | – |
| P/S | 1.1× | 0.7× (better) |
| P/B | 1.4× | 1.1× (better) |
| EV/EBITDA | 16.5× | 9.3× (better) |
| P/FCF | 11.1× (better) | 25.3× |
| FCF yield | 9.0% (better) | 4.0% |
| Fair value | $67.98 | $81.36 |
| Margin of safety | 27.4% | 65.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 1.6% | 4.9% (better) |
| Revenue growth, 5Y average | 9.8% | 14.9% (better) |
| Net income growth (TTM) | 14.6% | – |
| EPS growth (TTM) | 18.0% | – |
| EPS growth, 5Y average | 36.4% | – |
| Profitability | ||
| Gross margin | 57.6% | 61.1% (better) |
| Operating margin | 9.9% (better) | −45.1% |
| Net margin | 5.4% (better) | −48.0% |
| FCF margin | 9.7% (better) | 2.8% |
| Return on equity | 7.1% (better) | −54.3% |
| Return on invested capital | 5.2% (better) | −24.5% |
| Financial health | ||
| Debt / equity | 0.77 (better) | 0.87 |
| Net debt / EBITDA | 5.66 | 4.12 (better) |
| Interest coverage | 4.1× (better) | −30.9× |
| Current ratio | 1.49 | 1.98 (better) |
| Altman Z-score | 2.01 (better) | −0.23 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Payout ratio | 8.4% | – |
| Years of dividend growth | 0 | – |
| Dividend growth, 5Y average | −5.6% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 114% | 122% |
| Held by insiders | 0.47% | 2.7% |
| Insider net buying, 12 months | $0 | $792K (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 6.3% | 18.8% |
Go deeper
- CNMD stock overview
- CNMD income statement
- CNMD valuation and score
- ENOV stock overview
- ENOV income statement
- ENOV valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.